XTANDI (enzalutamide)
ANTIANDROGEN·METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER·+2
Astellas Pharma US
Indication
Non-metastatic castration-sensitive prostate cancer with biochem recurrence at high risk for mets
Non-metastatic castration-sensitive prostate cancer with biochemical recurrence at high risk for metastasis refers to an oncologic stage in men who have previously received definitive local therapy, such as radical prostatectomy or radiation therapy, and subsequently develop rising serum prostate-specific antigen levels without radiographically evident distant metastatic lesions on conventional imaging. Read more about Non-metastatic castration-sensitive prostate cancer with biochem recurrence at high risk for mets
1 drugs 1 manufacturers
Drugs that treat it
Common Non-metastatic castration-sensitive prostate cancer with biochem recurrence at high risk for mets therapies.
Filter & compare in the drug finder →Opens the drug finder with Non-metastatic castration-sensitive prostate cancer with biochem recurrence at high risk for mets preselected.
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonAbout Non-metastatic castration-sensitive prostate cancer with biochem recurrence at high risk for mets.
Non-metastatic castration-sensitive prostate cancer with biochemical recurrence at high risk for metastasis refers to an oncologic stage in men who have previously received definitive local therapy, such as radical prostatectomy or radiation therapy, and subsequently develop rising serum prostate-specific antigen levels without radiographically evident distant metastatic lesions on conventional imaging.
The disease remains castration-sensitive, meaning the malignant prostate epithelial cells retain sensitivity to androgen receptor pathway suppression and have not acquired androgen-independent growth mechanisms.
The high risk for developing metastatic spread is clinically characterized by aggressive recurrence dynamics, principally a rapid prostate-specific antigen doubling time of nine months or less, which reflects significant micro-metastatic disease burden and correlates with reduced metastasis-free survival and increased cancer-specific mortality.
- fda.gov
Non-metastatic castration-sensitive prostate cancer with biochemical recurrence at high risk for metastasis refers to an oncologic stage in men who have previously received definitive local therapy, such as radical prostatectomy or radiation therapy, and subsequently develop rising serum prostate-specific antigen levels without radiographically evident distant metastatic lesions on conventional imaging The high risk for developing metastatic spread is clinically characterized by aggressive recur...
- nih.gov
Non-metastatic castration-sensitive prostate cancer with biochemical recurrence at high risk for metastasis refers to an oncologic stage in men who have previously received definitive local therapy, such as radical prostatectomy or radiation therapy, and subsequently develop rising serum prostate-specific antigen levels without radiographically evident distant metastatic lesions on conventional imaging
- drozdogan.com
The disease remains castration-sensitive, meaning the malignant prostate epithelial cells retain sensitivity to androgen receptor pathway suppression and have not acquired androgen-independent growth mechanisms
- aacr.org
The disease remains castration-sensitive, meaning the malignant prostate epithelial cells retain sensitivity to androgen receptor pathway suppression and have not acquired androgen-independent growth mechanisms
- nih.gov
The high risk for developing metastatic spread is clinically characterized by aggressive recurrence dynamics, principally a rapid prostate-specific antigen doubling time of nine months or less, which reflects significant micro-metastatic disease burden and correlates with reduced metastasis-free survival and increased cancer-specific mortality
- pcf.org
The high risk for developing metastatic spread is clinically characterized by aggressive recurrence dynamics, principally a rapid prostate-specific antigen doubling time of nine months or less, which reflects significant micro-metastatic disease burden and correlates with reduced metastasis-free survival and increased cancer-specific mortality
Personalize your experience
Follow Non-metastatic castration-sensitive prostate cancer with biochem recurrence at high risk for mets and get updates as they land.
Create a free account
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.